Evidence map›Paper›PMID 24962326›Full record

Trial reportDrug and alcohol dependence2014

A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry.

Michael S Gordon, Timothy W Kinlock, Robert P Schwartz, Terrence T Fitzgerald, Kevin E O'Grady, Frank J Vocci

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Drug and alcohol dependence, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 5 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 5 syntheses or guidelines pooled it, 110 citations in OpenAlex.

  1. Routes of non-traditional entry into buprenorphine treatment programs.Substance abuse treatment, prevention, and policy · 2020
    Pooled it
  2. Pooled it
  3. Interventions for female drug-using offenders.The Cochrane database of systematic reviews · 2019
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Michael S GordonFriends Research Institute, Inc., 1040 Park Avenue, Suite 103, Baltimore, MD 21201, USA; Stevenson University, Department of Criminal Justice, 1525 Greenspring Valley Road, Stevenson, MD 21153, USA. Electronic address: mgordon@friendsresearch.org.
Timothy W KinlockFriends Research Institute, Inc., 1040 Park Avenue, Suite 103, Baltimore, MD 21201, USA; University of Baltimore, School of Criminal Justice, College of Public Affairs, 1420 N Charles Street, Baltimore, MD 21201, USA.
Robert P SchwartzFriends Research Institute, Inc., 1040 Park Avenue, Suite 103, Baltimore, MD 21201, USA; University of Maryland School of Medicine, Department of Psychiatry, 110 South Paca St., Baltimore, MD 21201, USA.
Terrence T FitzgeraldGlenwood Life Counseling Center, 516 Glenwood Avenue, Baltimore, MD 21212, USA.
Kevin E O'GradyUniversity of Maryland, 8082 Baltimore Avenue, College Park, MD 20740, USA.
Frank J VocciFriends Research Institute, Inc., 1040 Park Avenue, Suite 103, Baltimore, MD 21201, USA.
Counseling Center · USFriends Research Institute · USStevenson University · USUniversity of Maryland, College Park · US

Funding

Buprenorphine for PrisonersR01DA021579 · NIDA · FRIENDS RESEARCH INSTITUTE, INC. · PI KINLOCK, TIMOTHY W · 2007 to 2011
$2.7M
NIDA NIH HHS R01 DA021579NIDA NIH HHS R01DA021579
6 · The paper itself

Abstract

backgroundBuprenorphine is a promising treatment for heroin addiction. However, little is known regarding its provision to pre-release prisoners with heroin dependence histories who were not opioid-tolerant, the relative effectiveness of the post-release setting in which it is provided, and gender differences in treatment outcome in this population.

methodsThis is the first randomized clinical trial of prison-initiated buprenorphine provided to male and female inmates in the US who were previously heroin-dependent prior to incarceration. A total of 211 participants with 3-9 months remaining in prison were randomized to one of four conditions formed by crossing In-Prison Treatment Condition (received buprenorphine vs. counseling only) and Post-release Service Setting (at an opioid treatment center vs. a community health center). Outcome measures were: entered prison treatment; completed prison treatment; and entered community treatment 10 days post-release.

resultsThere was a significant main effect (p=.006) for entering prison treatment favoring the In-Prison buprenorphine Treatment Condition (99.0% vs. 80.4%). Regarding completing prison treatment, the only significant effect was Gender, with women significantly (p<.001) more likely to complete than men (85.7% vs. 52.7%). There was a significant main effect (p=.012) for community treatment entry, favoring the In-Prison buprenorphine Treatment Condition (47.5% vs. 33.7%).

conclusionsBuprenorphine appears feasible and acceptable to prisoners who were not opioid-tolerant and can facilitate community treatment entry. However, concerns remain with in-prison treatment termination due to attempted diversion of medication.

Indexed as

PrisonersPrisonsAdultBuprenorphineCombined Modality TherapyCounselingFemaleHeroin DependenceHumansMaleMiddle AgedNarcoticsTreatment OutcomeBuprenorphineNarcoticsBuprenorphineCorrectional settingsHeroinOpioid dependenceOpioid use disorderPrison

Identifiers

PMID24962326
PMCPMC4129444
OpenAlexW1979097541

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.